STAAR Surgical Co Stock Research

Market Summary

USD57.70-0.08

Market Closed

-0.14%

STAA Alerts

Big fall in earnings (Y/Y)

STAA Stock Price

STAA RSI Chart

STAA Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

87.64

Price/Sales (Trailing)

9.48

EV/EBITDA

62.35

Price/Free Cashflow

166.61

STAA Price/Sales (Trailing)

STAA Profitability

EBT Margin

16.02%

Return on Equity

11.67%

Return on Assets

9.34%

Free Cashflow Yield

0.6%

STAA Fundamentals

STAA Revenue

Revenue (TTM)

294.7M

Revenue Y/Y

16.34%

Revenue Q/Q

14.81%

STAA Earnings

Earnings (TTM)

31.9M

Earnings Y/Y

-71.78%

Earnings Q/Q

-53.7%

Price Action

52 Week Range

46.36112.27

(Low)(High)

Last 7 days

-2.6%

Last 30 days

-15.8%

Last 90 days

-3.6%

Trailing 12 Months

-11.4%

STAA Financial Health

Current Ratio

6.03

STAA Investor Care

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

0.63

Peers (Alternatives to STAAR Surgical)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	171.1B	30.9B	-4.16%	-10.76%	24.67	5.53	2.20%	7.40%
MDT	111.4B	30.8B	-8.29%	-14.72%	27.36	3.62	-3.19%	-17.32%
SYK	110.8B	19.0B	-5.21%	22.61%	46.98	6.01	8.73%	30.37%
ISRG	109.4B	6.4B	3.09%	43.51%	83.37	17.01	8.89%	-20.19%
COO	17.6B	-	-2.11%	9.04%	46.93	5.79	13.20%	-60.04%
MID-CAP
SWAV	7.2T	557.2M	0.46%	77.48%	82.2K	16.8K	86.42%	730.06%
PEN	12.0B	884.6M	11.70%	122.44%	1.8K	13.54	13.08%	200.12%
GMED	5.9B	1.1B	-2.60%	-14.42%	34.14	5.75	11.20%	53.04%
IRTC	3.2B	430.0M	-15.34%	-20.02%	-30.76	7.49	26.13%	15.73%
STAA	2.8B	294.7M	-15.81%	-11.38%	87.64	9.48	21.32%	9.45%
SMALL-CAP
SILK	1.2B	150.7M	-26.10%	-4.98%	-21.96	7.98	40.31%	1.80%
AVNS	1.2B	814.3M	-15.33%	-12.83%	25.98	1.42	6.96%	121.89%
BLFS	1.0B	163.2M	34.38%	72.90%	-6.86	6.15	17.84%	-885.82%
CSII	839.3M	239.8M	0.70%	0.15%	-22.16	3.5	-4.74%	-31.15%

Financials for STAAR Surgical

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	3.6%	295	284	279	262	243
Gross Profit	3.7%	232	223	219	203	189
S&GA Expenses	9.8%	197	180	168	159	151
R&D Expenses	6.6%	38.00	36.00	35.00	34.00	34.00
EBITDA	-1.1%	50.00	51.00	45.00	40.00	-
EBITDA Margin	-2.8%	0.18*	0.18*	0.17*	0.17*	-
Earnings Before Taxes	-14.9%	39.00	46.00	47.00	41.00	37.00
EBT Margin	-3.9%	0.16*	0.17*	0.16*	0.15*	-
Net Income	-17.8%	32.00	39.00	38.00	34.00	29.00
Net Income Margin	0.6%	0.14*	0.14*	0.13*	0.12*	-
Free Cahsflow	-21.6%	18.00	22.00	24.00	19.00	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	1.0%	419	415	395	376	351
Current Assets	0.4%	313	312	297	296	274
Cash Equivalents	4.0%	90.00	86.00	129	202	193
Net PPE	5.0%	53.00	51.00	48.00	43.00	40.00
Goodwill	0%	2.00	2.00	2.00	2.00	2.00
Liabilities	-3.3%	80.00	83.00	75.00	77.00	75.00
Current Liabilities	-9.0%	47.00	52.00	45.00	47.00	41.00
Shareholder's Equity	2.0%	339	332	320	299	276
Retained Earnings	3.7%	-69.92	-72.64	-78.49	-88.75	-101
Additional Paid-In Capital	1.3%	409	404	398	387	379
Accumulated Depreciation	2.6%	37.00	36.00	35.00	-	-
Shares Outstanding	0.2%	48.00	48.00	48.00	48.00	48.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-1.4%	35.00	36.00	41.00	39.00	33.00
Share Based Compensation	10.7%	23.00	20.00	19.00	17.00	15.00
Cashflow From Investing	8.0%	-143	-156	-114	-15.77	-14.02
Cashflow From Financing	-27.2%	6.00	8.00	8.00	7.00	13.00

Risks for STAA

What is the probability of a big loss on STAA?

93.5%

Probability that STAAR Surgical stock will be more than 20% underwater in next one year

88.8%

Probability that STAAR Surgical stock will be more than 30% underwater in next one year.

54.6%

Probability that STAAR Surgical stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does STAA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if STAAR Surgical was unfortunately bought at previous high price.

Drawdowns

Returns for STAA

Cumulative Returns on STAA

20.6%

10-Year Cumulative Returns

39.5%

7-Year Cumulative Returns

13.8%

5-Year Cumulative Returns

13.3%

3-Year Cumulative Returns

What are the long-term rolling returns for STAA?

FIve years rolling returns for STAAR Surgical.

Annualized Returns

Which funds bought or sold STAA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-30	Aspire Private Capital, LLC	unchanged	-	23,115	95,925	0.03%
2023-05-26	ProShare Advisors LLC	reduced	-13.76	65,237	544,278	-%
2023-05-23	ROYCE & ASSOCIATES LP	reduced	-24.45	-13,077	2,765,840	0.03%
2023-05-22	PUTNAM INVESTMENTS LLC	reduced	-4.06	347,356	1,663,280	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-0.85	953,905	4,069,900	-%
2023-05-22	Raleigh Capital Management Inc.	sold off	-100	-3,155	-	-%
2023-05-18	JPMORGAN CHASE & CO	added	14.13	3,703,000	11,055,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-13.07	407,000	3,209,000	-%
2023-05-17	Advisory Services Network, LLC	reduced	-91.7	-104,191	12,790	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	added	2.08	-100,794	237,846	-%

Latest Funds Activity

Are funds buying STAA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own STAA

No. of Funds

STAA Alerts

Big fall in earnings (Y/Y)

STAAR Surgical News

Schedule 13G FIlings of STAAR Surgical

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	11.01%	5,306,915	SC 13G/A
Jan 23, 2023	blackrock inc.	11.9%	5,738,044	SC 13G/A
Jan 19, 2023	baillie gifford & co	10.87%	5,240,456	SC 13G/A
Feb 14, 2022	palo alto investors lp	2.40%	1,140,511	SC 13G/A
Feb 10, 2022	vanguard group inc	10.44%	4,970,324	SC 13G/A
Jan 27, 2022	blackrock inc.	11.8%	5,622,956	SC 13G/A
Jan 26, 2022	baillie gifford & co	11.62%	5,529,868	SC 13G/A
Jan 25, 2022	blackrock inc.	11.8%	5,622,956	SC 13G/A
Oct 01, 2021	broadwood partners, l.p.	18.1%	0	SC 13D/A
Sep 10, 2021	vanguard group inc	10.10%	4,787,522	SC 13G/A

STAA Fair Value

Show Fair-Value

Recent SEC filings of STAAR Surgical

View All Filings

Date Filed	Form Type	Document
May 09, 2023	4	Insider Trading
May 09, 2023	4	Insider Trading
May 04, 2023	8-K	Current Report
May 03, 2023	10-Q	Quarterly Report
May 03, 2023	8-K	Current Report
Apr 26, 2023	ARS	ARS
Apr 26, 2023	DEF 14A	DEF 14A
Apr 26, 2023	DEFA14A	DEFA14A
Mar 29, 2023	3	Insider Trading
Mar 29, 2023	3	Insider Trading

Latest Insider Trading transactions for STAA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-08	Foust Warren	acquired	-	-	20,331	chief operating officer
2023-05-08	Michna Magda	acquired	-	-	14,047	chief clinical, regulatory,
2023-03-20	Francese James E	sold (taxes)	-49,469	62.07	-797	sr. vp, comm. ops., na, apac
2023-03-20	Gesten Samuel J	sold (taxes)	-55,366	62.07	-892	chief legal officer
2023-03-20	Holliday Keith	sold (taxes)	-56,297	62.07	-907	chief technology officer
2023-03-20	Barnes Scott D	sold (taxes)	-56,545	62.07	-911	chief medical officer
2023-03-17	Holliday Keith	sold	-51,001	61.97	-823	chief technology officer
2023-03-10	Barnes Scott D	sold (taxes)	-16,139	56.63	-285	chief medical officer
2023-03-10	Barnes Scott D	acquired	-	-	10,555	chief medical officer
2023-03-10	Holliday Keith	sold (taxes)	-16,082	56.63	-284	chief technology officer

About STAAR Surgical

Caren L. Mason

www.staar.com

810

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAA Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Apr. 01, 2022
Income Statement [Abstract]
Net sales	$ 73,528	$ 63,200
Cost of sales	15,966	13,936
Gross profit	57,562	49,264
Selling, general and administrative expenses:
General and administrative	18,098	11,940
Selling and marketing	26,354	17,270
Research and development	10,310	7,941
Total selling, general and administrative expenses	54,762	37,151
Operating income	2,800	12,113
Other income (expense), net:
Interest income (expense), net	1,822	(6)
Gain (loss) on foreign currency transactions	34	(915)
Royalty income		273
Other income, net	63	62
Total other income (expense), net	1,919	(586)
Income before income taxes	4,719	11,527
Provision for income taxes	2,009	1,925
Net income	$ 2,710	$ 9,602
Net income per share:
Basic	$ 0.06	$ 0.20
Diluted	$ 0.05	$ 0.19
Weighted average shares outstanding:
Basic	48,247	47,755
Diluted	49,500	49,288

STAA Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 30, 2022
Current assets:
Cash and cash equivalents	$ 89,968	$ 86,480
Investments available for sale	113,879	125,159
Accounts receivable trade, net of allowance for credit losses of $43 and $20, respectively	63,494	62,447
Inventories, net	27,808	24,161
Prepayments, deposits and other current assets	17,722	13,476
Total current assets	312,871	311,723
Investments available for sale	13,445	13,902
Property, plant and equipment, net	53,453	50,921
Finance lease right-of-use assets, net	303	342
Operating lease right-of-use assets, net	31,182	30,270
Intangible assets, net	165	173
Goodwill	1,786	1,786
Deferred income taxes	4,744	4,824
Other assets	956	957
Total assets	418,905	414,898
Current liabilities:
Accounts payable	9,102	11,576
Obligations under finance leases	171	169
Obligations under operating leases	3,538	3,524
Allowance for sales returns	5,303	5,706
Other current liabilities	28,949	30,741
Total current liabilities	47,063	51,716
Obligations under finance leases	167	210
Obligations under operating leases	28,030	27,136
Deferred income taxes	1,369	1,489
Asset retirement obligations	218	220
Pension liability	3,134	1,935
Total liabilities	79,981	82,706
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 60,000 shares authorized: 48,331 and 48,212 shares issued and outstanding at March 31, 2023 and December 30, 2022, respectively	483	482
Additional paid-in capital	409,303	404,189
Accumulated other comprehensive gain (loss)	(937)	156
Accumulated deficit	(69,925)	(72,635)
Total stockholders’ equity	338,924	332,192
Total liabilities and stockholders’ equity	$ 418,905	$ 414,898